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Abstract
Background: By the use of PSMA positron emission tomography (PET) detection of prostate cancer lesions with a
high sensitivity and specificity combined with a favorable lesion to background contrast is feasible. Therefore,
PSMA-PET is increasingly used for planning of radiotherapy treatment; however, any data on intermediate-term
outcome is missing so far.
Methods: Patients with high-risk or very high risk prostate cancer, referred for salvage radiotherapy (SRT, n = 22)
between 2013 and 2015, underwent PSMA-PET prior to therapy. Irradiation was planned on PET data with boost to
macroscopic tumors/metastases. Treatment related toxicity was measured using Common Terminology Criteria for
Adverse Events (CTCAE, v4.0).
Result: Findings in PSMA-PET led to treatment modifications in 77% of SRT patients compared to available CT
information. One patient did not receive irradiation due to disseminated disease, the other patients received
increased boost doses to macroscopic disease and/or inclusion of additional target volumes. Toxicity was low as
only 2 patients reported toxicities > grade 1. With a Median follow-up time of 29 in patients that were not lost to
follow-up, prolonged PSA responses below baseline were observed in the majority of patients (14 of 20). In
hormone-naïve SRT patients (n = 11), radiotherapy led to prolonged PSA decrease in 8/11 patients, however with 3
of these 8 patients receiving repeated PSMA based irradiation of novel lesions during follow-up.
Conclusion: PSMA-PET guided planning of radiotherapy led to change of treatment in the majority of
patients. Treatment related toxicity was well tolerated and promising results regarding intermediate-term PSA
decrease were observed.
Trial registration: No trial registration was performed due to retrospective evaluation.
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Background
Both radiotherapy and radical prostatectomy are primary
treatment modalities for localized prostate cancer. Cancer
specific mortalities after these treatments is around 1%
after 10 years for low and intermediate risk patients [1].
However, patient outcome is much less favorable for high-
risk or very high-risk prostate cancer as these patients
have a 10 year prostate specific mortality between 10 and
20% following definitive radiotherapy or surgery [2, 3].
This is probably due to the existence of unknown micro-
metastatic disease prior to local treatment in a certain
proportion of patients.
In case of biochemical failure (BF) after radical prostatec-
tomy early salvage radiotherapy is the recommended treat-
ment [4]. Postoperative treatment decision is commonly
based on serum prostate specific antigen (PSA) values. One
drawback of this approach is missing spatial information of
recurrence, which would be highly relevant for the planning
of a localized treatment like radiotherapy. Increased
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radiation dose was demonstrated to improve biochemical
recurrence free survival after primary radiotherapy [5, 6]
and was suggested to improve relapse-free survival in
meta-analyses of retrospective data from salvage radiother-
apy (SRT) patients [7, 8], a hypothesis which is currently
evaluated by the phase 3 SAKK 09/10 trial [9]. However,
dose intensification led to increased toxicity in primary
treatment [5, 6] and was shown to negatively impact pa-
tients quality of life regarding urinary symptoms after SRT
[9]. As a result, accurate detection of individual spread of
disease or recurrence patterns would be highly warranted.
Moreover, in selected oligometastatic patients radical
treatment of identified metastatic lesions could further
improve outcome.
Uncertainties about optimal treatment exist in a high
risk post-operative setting with either high persisting
PSA values after surgery or rapidly increasing PSA levels.
If these patients benefit from SRT is not proven to date.
In case of pre-SRT PSA values higher than 2 ng/ml the
4-year progression-free probability after SRT was only
19% whereas it is around 52% for patients with PSA
values ≤2 ng/ml [10].
Recently there is a rapid increasing interest in positron
emission tomography (PET) imaging using the tracer
prostate specific membrane antigen (PSMA). PSMA is
highly overexpressed at the surface of prostate cancer
cells [11] and PSMA-PET was shown to be both, highly
sensitive and highly specific, even in cases of low PSA
values (<1 ng/mL) [12–15]. Thus, PSMA-PET may be
especially relevant for radiotherapy treatment planning
in a high-risk salvage setting. Due to high sensitivity and
specificity of PSMA-PET even very small nodal metasta-
ses (<8 mm) are reliably detectable [16]. Additionally,
due to the whole body approach even previously unex-
pected (distant) metastases can be localized. Thus, im-
provements in imaging may lead to an improvement in
patient’s outcome. Therefore, we report on patients that
received PSMA PET for high-risk SRT, i.e. patients with
doubtful benefit of local standard treatment and focus
und intermediate-term PSA control in these patients.
Patients and methods
Patient characteristics
Patients presenting at the department of radiation oncol-
ogy for salvage radiotherapy after prostatectomy were
stratified for their individual risk. High-risk patients as
defined as pre-therapeutic PSA values above 20 ng/ml,
Gleason score 8 or higher, persisting PSA values after
radical prostatectomy (> 0.6 ng/ml), PSA values before
SRT above 2 ng/ml or metastatic regional lymphnodes
(diagnosed during prostatectomy), were referred for a
pre-therapeutic PSMA PET/CT between 2013 and De-
cember 2015. If irradiation was still indicated after
PSMA PET/CT imaging, patients were irradiated based
on data of PSMA PET/CT. Originally 22 patients were
scheduled for salvage radiotherapy (SRT) of the prostate
bed. Median Age at the time of treatment was 65 years.
Further details on the patient characteristics can be
found in Table 1.
PET imaging
Images were acquired on a PET/CT device (Gemini TF 16
Astonish, Philips Medical Systems, Cleveland, OH, USA).
Patients were examined in supine position from base of
scull to the proximal femora 62 ± 35 min after intravenous
injection of 113 ± 13.3 MBq of [68Ga]PSMA-HBED-CC
(PSMA-11) (PSMA). In all patients, a diagnostic, contrast-
enhanced CT was acquired and used for attenuation cor-
rection. For one patient, no information about injection
time and injected dose was available, two patients received
radiotherapy planning based on 18F–Cholin PET, and sub-
sequently underwent PSMA-PET imaging.
The findings in PET imaging were categorized as fol-
lows: Local recurrence (T) included recurrence within the
prostate bed and seminal vessels. Lymph node metastases
within the regional drainage of the prostate was classified
as N or as M1a if outside the regional drainage, further
metastases (which were in all cases bone metastases) were
scored as M1b.
Radiotherapy treatment and clinical follow-up
Intensity-modulated radiotherapy (IMRT) was performed
in all patients undergoing radiotherapy after PSMA-PET
imaging. Almost all patients were treated with helical
Table 1 Patient characteristics
Salvage Radiotherapy (SRT) n = 22
PSA before surgery (ng/ml) 18.9 (3.14–115) Avg. (range)
Postoperative Gleason score 8 (6–10) Avg. (range)
PSA before SRT 6.1 (0.2–34.5) Avg. (range)
Months between surgery and SRT 29 (2–201) Avg. (range)












PSA < 0.1 ng/ml 23
PSA > 0.1 ng/ml 9
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tomotherapy (Accuray, USA), two patients were treated
with the Novalis™ radiosurgery system (Varian, USA;
Brainlab, Heimstetten, Germany) and 2 patients received
irradiation by linear accelerators (Varian, USA) using a
volumetric modulated arc approach.
Radiotherapy prescription was as follows: Usually sin-
gle fraction doses of 1.8 Gy were prescribed to a total
dose of 66.6 Gy to prostate bed, including the base of
seminal vesicles and the complete seminal vesicle in case
of pT3b tumors. In the histologically described high-risk
regions (with positive surgical margins or extracapsular
spread) a simultaneous integrated boost (SIB) was ap-
plied to a cumulative total dose of 70.3 Gy. In case of
PSMA-PET evidence of macroscopic local recurrence
the SIB dose was increased to a maximal dose of 74 to
77.7 Gy. The lymphatic drainage was not irradiated un-
less if PET imaging revealed pelvic lymphnode metasta-
sis. If the latter one was evident the lymphatic drainage
was irradiated to a total dose of 54.0 Gy and macro-
scopic lymphnodes received a SIB to 66 Gy. Evident
bony metastases were irradiated to a total dose of 42–
66 Gy, depending on location and size. Androgen
deprivation therapy (ADT) was prescribed according to
the preference of the treating urologist.
Acute toxicities were scored at least every two
weeks during treatment and at the end of therapy by
the treating physician according to common termin-
ology criteria for adverse events (CTCAE), version
4.0. Information about PSA values, toxicities and
ADT was collected from the treating urologist and by
patient interviews. PSA values were usually measured
every 3 months following radiotherapy by the urolo-
gist, who was responsible for decision-making about
initiation or continuation of ADT.
Statistical calculations and software
Statistical analyses and plots were generated by Graph-
Pad Prism 6 (Graphpad Software, La Jolla, CA, USA)
and Inkscape 0.91 (www.inkscape.org).
Results
Modification of treatment according to findings in PSMA
PET/CT
In high-risk patients PSMA-PET led to treatment modi-
fications in 77% patients referred for SRT. One patient
presented with disseminated metastases and SRT was
therefore omitted. Figure 1 depicts PSMA-PET based
treatment modifications.
Toxicity
Radiotherapy could be delivered as planned in all pa-
tients and was well tolerated (Table 2). Only 2 of 21
treated patients developed acute toxicities greater grade
1 according to CTCAE v4.0 (one case of grade 2 non-
infective cystitis and one case of grade 2 diarrhea). Dur-
ing follow-up no late toxicities greater grade 1 were
observed.
Fig. 1 Treatment modifications after PSMA-PET in patients referred for salvage radiotherapy
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Follow-up
One patient was lost to follow-up, median follow up time
in the remaining irradiated 20 patients was 29 months
(range: 12–49). Median PSA values at the time of last
follow-up were 0.15 ng/ml (range: 0–8.45). 11 of these pa-
tients did not receive androgen deprivation therapy (ADT)
prior or concomitant to SRT. During follow-up only one
of these patients started ADT; however, three patients re-
ceived PSMA-PET based irradiation of de novo lesions
during follow-up. In this group of ADT naive patients the
mean PSA value after an average follow-up time of
26 months (12–34) was 1.4 ng/ml (range: 0–5) with 8 out
of 11 patients still presenting PSA values lower than prior
to SRT. Figure 2 depicts the percentual PSA change be-
tween pre-SRT and last follow-up in all patients after SRT.
Out of 9 SRT patients with prior/concomitant ADT, 5
patients started ADT concomitantly to radiotherapy while
4 patients already presented a history of, sometimes long-
term, ADT medication (average: 20 months, range: 3–
58 months). Some of these patients received SRT with
already rising PSA values during ADT (i.e. beginning of
hormone refractory situation), which is probably the rea-
son why some patients already presented increasing PSA
values during intermediate-term follow-up (Fig. 2). 6 of
the patients with ADT had substantial intermediate-term
PSA responses. In three patients ADT could be or had to
be omitted during follow-up.
Patients were grouped regarding clinical risk factors
(Median initial PSA value and PSA value at the time of
SRT, Gleason score up to 7 or higher, Median PSA Nadir
value, postoperative T stage >3a and postoperative N+)
and regarding PET findings (isolated local recurrence, no
evidence of PSMA tracer uptake, any distant metastases
or only lymphnode metastases N+ and/or Ma+). Median
response rates for these different groups are summarized
in Table 3. Differences in response were only observed in
patients with pN+ and patients receiving salvage radio-
therapy without any lesion in PSMA-PET (Median PSA
response: −9% for PSMA negative patients versus −79% in
case of irradiated PSMA lesions and +34% in case of pN+
versus −79% for pN0).
Discussion
So far the impact of PSMA PET/CT on treatment outcome
after radiotherapy is unknown. Here we report the first
study with clinical meaningful follow-up longer than two
years. We found first evidence that inclusion of PSMA
PET/CT positive lesions for radiotherapy planning leads to
favorable PSA responses in the majority of high-risk and
very high-risk patients. Additionally, no high-grade acute
Table 2 Acute toxicities in irradiated patients
Toxicity Grade 0 Grade 1 Grade 2
Salvage Radiotherapy (SRT) n = 21
Proctitis 17 4 0
Diarrhea 14 6 1
Cystitis 13 7 1
Polakisuria 15 6 0
Fatigue 11 10 0
Other 19 2 0
Fig. 2 Percentual decrease/increase of PSA levels in individual patients from the time of salvage radiotherapy until last follow-up (average time:
30.2 months). Patients without (w/o) androgen deprivation therapy (ADT) in black and patients with ADT concomitant to radiotherapy in grey.
Patient 11 initiated ADT during follow-up, patients 16 and 19 discontinued ADT longer than 6 months before measuring last PSA value. T+, N+,
Ma + or Mb + indicates (irradiated) PSMA-PET findings of local, lymphnode or distant lymphnode (Ma+) or bony (Mb+) recurrences. Patients 3, 8
and 9 underwent re-irradiation of novel metastases during follow-up
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toxicities were observed. Grade 2 toxicities were seen in
9.5% (2 of 21) of the irradiated patients only. The PET
adapted radiotherapy planning can be regarded well toler-
able, although PET imaging led to higher focal irradiation
doses or inclusion of additional target volumes in 77% of
patients (17 of 22 patients with SRT). Favorable
intermediate-term PSA responses were observed in 8 of 11
hormone-naïve patients.
Currently data on PSMA-PET guided therapy is sparse
and only a few studies assessed the impact of PSMA-PET
on radiotherapy planning: According to previous retro-
spective studies PSMA-PET altered treatment decisions in
26% to 33% [17, 18] of primary treated patients and 42%
to 61% of SRT patients [18, 19]. One study investigated
treatment changes for a very heterogeneous group of pa-
tients, with the majority being SRT patients (67%), an re-
ported an overall treatment adaptation rate of 46% [20].
Another recent publication which only analyzed SRT pa-
tients with PSA values below 1.0 ng/ml detected PSMA
positive lesions in 54%, which potentially altered radio-
therapy treatment of these patients [21]. Our data confirm
the observations that radiotherapy is often altered in SRT
after PSMA-PET imaging. An important difference is the
rate of 77% in SRT which is higher than the average rate
of the cited publications. This is probably due to a more
restrictive use of PSMA-PET imaging in patients de-
scribed here. Typically PSMA-PET was only applied in
very high risk situations, in which the solely use of local
therapies could be of doubtful benefit for patients.
The use of PSMA-PET is rapidly increasing in many
countries, including Germany and Australia. This led to a
recent expression of opinion from several experts in the
field that the use of PSMA-PET has reached almost plague-
like proportions [22]. National guidelines usually only
propose PSMA-PET in case of recurrent disease as an
optional method (German S3 guideline) or don’t even men-
tion PSMA-PET (NCCN prostate cancer guidelines version
2.2017) [23, 24]. Due to the novel nature of PSMA-PET any
long-term data, that include relevant endpoints like overall
survival and prostate cancer specific survival, are missing so
far. To our best knowledge, there is only limited data with
short follow up, e.g. a mean follow-up of 8 months was re-
cently published [19]. Our data has up to now the longest
follow-up time and reveals interesting aspects in high-risk
patients. Especially the finding that 8 of 11 ADT naïve pa-
tients receiving SRT have long-lasting PSA responses
>2 years seems encouraging for the future use of PSMA
based radiotherapy. Furthermore, in absence of this oppor-
tunity these very high risk patients would probably have
been referred for ADT in the vast majority of cases. Andro-
gen deprivation commonly fails after 2–3 years in case of
macroscopic disease [25, 26]. Even in lower-risk patients
with average PSA levels of 1.02 at the time of ADT initi-
ation 13% of patients showed clinical progression within an
average follow-up time of 2 years in a larger retrospective
analysis [27]. Based on the relatively low case number it
seems difficult to draw conlcusions on sub-groups that po-
tentially benefit or do not benefit from PSMA-PET based
radiotherapy. In our study patients with high-risk factors
but without any evidence of PSMA lesions and patients
with histological proven lyhmnode metastases (pN+)
seemed to benefit less. However these findings should be
validated in larger patient cohorts.
For the here described high-risk constellation SRT candi-
dates clinical evidence and guidelines are sparse. Based on
a retrospective analysis from Trock and colleagues com-
mon criteria to determine if patients benefit from SRT are:
SRT within 2 years of BCR and no persisting PSA levels
after surgery [28], however another study proved positive
effects of SRT even with longer time intervals, at least for
T3 tumors [29]. While the study from Trock did not find a
correlation between pre SRT PSA values and outcome after
radiotherapy, although patients with pre-SRT PSA values
up to 57 ng/ml were included, other studies found a posi-
tive effect of SRT mainly in patients with PSA values below
1 ng/ml [30]. The multi-istitutional analysis from Ten-
dulkar and colleagues supports the notion that optimal
SRT should be delivered as early as possible with low PSA
values [31]. The ideal treatment for patients with higher
PSA values or a longer time interval between surgery and
intervention is therefore unclear.
In case of oligometastastatic prostate cancer radical
local therapy including radiotherapy seem to be associ-
ated with favourable patient outcome, although any pro-
spective data on this important issue is lacking [32, 33].
Conclusions
Our data, although limited by its retrospective nature and
small sample size, support the role of radiotherapy in
Table 3 Risk factors and their association with intermediate-term
PSA response
Risk factor - +
Gleason score > 8 −18 −81
Median Initial PSA value −76 −94
Median PSA Nadir −78 −85
Median PSA before irradiation −78 −86
Postoperative T stage >3a −78 −85
Postoperative N+ −79 +34
PSMA-PET findings
No detectable lesions −79 −9
Isolated local recurrence −89 −42
Distant metastases −76 −89
Lymphnode metastases (N+/M1a)a −76 −99
aDue to the low number of isolated regional recurrences (n = 2) these patients
were combined with M1a patients for analyses
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combination with state of the art PSMA-PET imaging for
individually tailored treatment. The low rate of toxicities
and the high rate of durable PSA response are encour-
aging and merit further prospective evaluation. We are
well aware that due to restrictions of imaging resolution,
PET based radiotherapy mostly only hits the tip of the ice-
berg in patients presenting a tumor stage where micro-
scopic spread beyond PET lesions seem to be the rule and
not the exception. Therefore we decided against the use of
classical criteria for biochemical recurrence, since prob-
ably almost all patients described here will relapse. Instead
the relative increase/decrease of PSA levels compared to
the level at initiation of radiotherapy was applied. As PSA
levels are not only highly relevant for the psychological
wellbeing of prostate cancer patients, but also for decision
making regarding ADT or therapy intensification, an
intermediate-term gain of PSA levels below baseline
seems to be an appropriate endpoint in this setting. In this
regard our findings indicate the safety and effectiveness of
PSMA based radiotherapy in the described high-risk pa-
tients, having in mind that prospective data for optimal
treatment for these patients is currently missing. However
these patients should be informed that the radiothera-
peutic approach is probably only able to delay ADT as
during follow-up arising of novel lesions seems to be fre-
quent, which however often can be temporary treated lo-
cally, too (3 of 11 cases received PSMA-PET based
irradiation during follow-up).
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